Page 451 - Essential Haematology

Index / 437

embryonic stem cells 5 erythropoietin 7, 8, 17–19 replacement in haemophilia A
end-stage renal disease, anaemia 28 349
erythropoietin therapy 19 in renal failure 386–7 venous thrombosis association
endocrine therapy, thalassaemia haematological malignancies with high levels 368
major 98 168 factor VIII gene, haemophilia A
endothelial cells 321, 323–4 myelodysplasia 219 346, 347
nitric oxide 320, 321, 324 primary myelofi brosis 211 factor VIIIa 320, 321
enteropathy-associated T-cell recombinant 18–19 factor IX 322
lymphoma 270 therapy clotting assay 352
enzyme replacement therapy, anaemia of chronic disorders factor IX defi ciency 352
Gaucher’s disease 125 47 clinical features 350
eosinophil(s) 109, 111 indications 18–19 coagulation factor activity 349
eosinophilia 120–1 transfusion requirement disease severity 349
eosinophilic granuloma 122 reduction 410 inheritance 350
eosinophilic leucocytosis 120–1 erythropoietin receptors 18 laboratory fi ndings 350
Epstein–Barr virus (EBV) Escherichia coli, haemolytic uraemic factor IXa 320, 321
allogeneic stem cell syndrome 338 factor IX–prothrombin complex,
transplantation 309 essential thrombocythaemia (ET) freeze-dried concentrates
antibody testing 138 203, 208–10 411
Burkitt lymphoma 268 clinical features 206 factor X 320, 321, 322
haematological malignancies clinical signs 209 factor Xa 320, 321
153–4, 170, 171 course 210 factor Xa inhibitors 375–6
HIV infection 391 diagnosis 209 factor XI 322, 325
Hodgkin lymphoma 246 JAK2 gene mutation 209 factor XIII 322, 325
infectious mononucleosis 135 laboratory fi ndings 209, 210 FANCD2 gene 289
post-transplant prognosis 209–10 Fanconi’s anaemia 289, 290,
lymphoproliferative treatment 209–10 291
diseases 312 venous thrombosis 369 Felty’s syndrome 385
eptifi batide 379 Evans’ syndrome 83 ferric carboxymaltose 45
erythroblastosis fetalis 421, 422 exchange transfusion, haemolytic ferric hydroxide-sucrose 45
erythroblasts 16, 17 disease of the newborn ferrireductase 39
erythrocyte sedimentation rate 422 ferritin 34, 36
(ESR) extrinsic Xase 322, 323, 325 serum levels 43, 44
acute phase proteins 394–5 iron chelation therapy 56
thrombophilia screening 370 F iron overload 51, 53
erythrocytes 16–17 factor II inhibitors 376 normal values 425
erythrocytosis see polycythaemia factor V 322, 325 synthesis regulation 35–7
erythroid colony-forming unit factor V Leiden gene mutation ferritin light chain gene mutations
(CFU E ) 16 364–6 53
erythroid hyperplasia 31 factor VIII 322, 325 ferroportin 38
erythroid hypoplasia 31 alloantibodies 359 gene mutations 53
erythropoiesis 16–17 antibodies 352 ferrous sulphate 45
assessment in anaemia 29, 32 autoantibodies 359 ferumoxytol 45
bone marrow precursors 19 clotting assay 348 fetal haemoglobin (Hb F) 19–20,
eff ective 32 fetal blood levels 349 22, 89
ineff ective 29, 31, 32 freeze-dried concentrates 411 switch to adult 90–1
pregnancy requirements 414 inhibitors 352 fetomaternal alloimmune
regulation 17–19 non-O blood group 367 thrombocytopenia 418